Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
I gleaned that the market has likely reflected significant headwinds on BMY's ability to recover.
Source: https://seekingalpha.com/article/4619010-bristol-myers-squibb-gift-arrived?source=feed_all_articles
Perhaps this is why BMY's and PFE's stock performances have been somewhat underwhelming over the past few years, compared to its pharmaceutical peers and the wider market.
With the twin risks of falling Revlimid revenues and drug pricing pressures being effectively managed, and not impacting BMY's growth potential, my conclusion is that BMY's share price is being artificially weighed down by these concerns.
With the twin risks of falling Revlimid revenues and drug pricing pressures being effectively managed, and not impacting BMY's growth potential, my conclusion is that BMY's share price is being artificially weighed down by these concerns.